Contact Us
Drug Search Results
More Filters [+]

Zofenopril

Alternative Names: zofenopril
Latest Update: 2024-11-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ACE Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Austria | Belgium | Bosnia | Bulgaria | Chile | Colombia | Dominican Republic | Egypt | Estonia | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Spain | Sweden | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Menarini
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zofenopril

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Myocardial Infarction|Hypertension|Acute Respiratory Distress Syndrome

Phase 3: Hypertension|Ventricular Dysfunction, Left

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
Masolino

P4

Completed

Hypertension

2022-04-28

MASOLINO Study

P4

Active, not recruiting

Hypertension

2022-04-16

Masaccio

P4

Completed

Hypertension

2021-12-22

MASACCIO

P4

Completed

Hypertension

2021-11-18

Recent News Events

Date

Type

Title

12/01/2023

PubMed

 Extemporaneous combination therapy with amlodipine/zofenopril in hypertensive patients: a real-world data analysis in Italy.

10/25/2023

PubMed

 The effect of zofenopril on the cardiovascular system of spontaneously hypertensive rats treated with the ACE2 inhibitor MLN-4760.

09/26/2023

News Article

 Ambrettolide Market 2023 Global Insights and Business Scenario

09/13/2023

PubMed

 Effects of Zofenopril on Arterial Stiffness in Hypertension Patients.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions